摘要/Abstract

摘要： 特应性皮炎是一种慢性炎症性皮肤病，主要与Th2型信号通路的变化有关。白细胞介素-4（interleukin-4，IL-4）和IL-13的表达增加使聚丝蛋白减少，从而导致皮肤屏障缺陷。Janus激酶-信号转导及转录激活因子（Janus kinase-signal transducer and activator of transcription，Jak-STAT）信号通路与特应性皮炎的发病机制密切相关，抑制Jak-STAT信号通路治疗特应性皮炎是一种有潜力的方法。Janus激酶（Janus kinase，JAK）抑制剂在对JAKs抑制的选择上可分为第一代JAK抑制剂和第二代JAK抑制剂。该综述通过对第一代和第二代JAK抑制剂在临床试验中的疗效和安全性进行总结，阐明JAK抑制剂在特应性皮炎治疗中的临床应用研究进展。
关键词: 特应性皮炎, Jak-STAT信号通路, JAK抑制剂
Abstract:
Atopic dermatitis is a chronic inflammatory skin disease, which is mainly related to changes in Th2 type signaling pathways. Increased expression of interleukin-4 (IL-4) and IL-13 reduces filaggrin, which leads to skin barrier defects. The Janus kinase-singal transducer and activator of transcriprion (Jak-STAT) signaling pathway is closely related to the pathogenesis of atopic dermatitis. Inhibiting the Jak-STAT signaling pathway is a potential method to treat atopic dermatitis. Janus kinase (JAK) inhibitors can be divided into first-generation and second-generation JAK inhibitors in the selection of JAKs′ inhibition. By summarizing the efficacy and safety of the first-generation and second-generation JAK inhibitors in clinical trials, the clinical research progress of JAK inhibitors in the treatment of atopic dermatitis is clarified.
Key words: atopic dermatitis, Jak-STAT signaling pathway, JAK inhibitors


PDF全文下载地址:

点我下载PDF